Frankfurt
02.09.26 | 15:10
5,010 Euro
+17,61 % +0,750
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 12.08. | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.08. | PolyPid GAAP EPS of -$0.35 beats by $0.03 | 5 | Seeking Alpha | ||
| 12.08. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 1.117 | GlobeNewswire (Europe) | FDA Accepted D-PLEX100 NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization... ► Artikel lesen | |
| 12.08. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | 7 | GlobeNewswire (USA) | ||
| 29.07. | PolyPid rises as lead product granted FDA priority review | 2 | Seeking Alpha | ||
| 29.07. | PolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up | 1 | RTTNews | ||
| 29.07. | PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | 582 | GlobeNewswire (Europe) | PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million... ► Artikel lesen | |
| 29.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | H.C. Wainwright reiterates Buy on PolyPid stock, $13 target | 3 | Investing.com | ||
| 21.07. | PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada | 6 | Contract Pharma | ||
| 21.07. | PolyPid Partners With Azurity In D-PLEX100 Commercialization Deal Worth Over $320 Million | 1 | pulse2.com | ||
| 21.07. | PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada | 4 | Investing.com | ||
| 21.07. | PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | 446 | GlobeNewswire (Europe) | PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to... ► Artikel lesen | |
| 15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | PolyPid Ltd.: PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 | 212 | GlobeNewswire (Europe) | If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA... ► Artikel lesen | |
| 01.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | PolyPid Q1 2026 Earnings Call: Complete Transcript | 5 | Benzinga.com | ||
| 13.05. | PolyPid GAAP EPS of -$0.35 beats by $0.08 | 1 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,35 | +2,79 % | BioNTech-Aktie: Im September könnte der große Durchbruch warten | Nach starken Studiendaten von Moderna ist auch die BioNTech-Aktie deutlich angesprungen. Schon im September kann das Unternehmen nun selbst nachlegen. Dann werden neue Ergebnisse aus mehreren Krebsprogrammen... ► Artikel lesen | |
| EVOTEC | 3,310 | +5,08 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| AMGEN | 381,55 | +0,93 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 8,900 | +1,95 % | Novavax announces regulatory approvals for updated COVID shot | ||
| PALATIN TECHNOLOGIES | 11,780 | +1,20 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,182 | +2,60 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,100 | +0,17 % | Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. | ||
| DEFENCE THERAPEUTICS | 0,329 | +3,79 % | Defence Therapeutics Inc: Defence expands radiopharmaceutical development program | ||
| NUREXONE BIOLOGIC | 0,380 | +1,06 % | NurExone Biologic: Vom Rückenmarks-Trauma bis zur Sehnerv-Regeneration | ||
| ABIVAX | 97,50 | -0,41 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,139 | +2,71 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| IBIO | 1,115 | +2,95 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,62 | +3,17 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia | Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population
More than 90% of plozasiran-treated patients achieved triglycerides... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,844 | -2,94 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,312 | -2,65 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen |
POLYPID LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,750 (+17,61 %) liegt der Kurs bei 5,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.